On Mindbloom's 6-session program, cancellation fees rise from $150 to the full $1,290 as prescriptions ship.
Mindbloom is a real, operating U.S. telehealth company, and its new-client ketamine programs cost $1,290 to $2,970 out of pocket as of October 12, 2026. Licensed clinicians at affiliated, independently owned practices screen each client and may prescribe compounded ketamine for sessions at home. Running a telehealth company is separate from drug approval, and compounded ketamine is not approved by the U.S. Food and Drug Administration (FDA) for any psychiatric use.
Whether a Mindbloom program is worth the cost depends on a clinician's screening, the state you live in and what you can pay.
Mindbloom is a real, operating U.S. telehealth company that publishes its prices, refund schedule and state list. Mindbloom, Inc. describes itself as a platform that provides services to affiliated psychiatric practices that are independently owned and operated. Mindbloom says it does not own, direct or control the clinicians who provide care. Its website is reviewed by Mindbloom Medical Group, P.C., according to the footer on the Mindbloom pricing page.
Clinicians working with Mindbloom may prescribe ketamine compounded by pharmacies under Section 503A of the federal Food, Drug, and Cosmetic Act, as Mindbloom's safety page explains. The FDA has not determined that this compounded ketamine is safe and effective for anxiety, depression or other mental health conditions. Ketamine itself is a Schedule III controlled substance.
New-client programs cost $1,290 for 6 sessions, $2,220 for 12 sessions and $2,970 for 18 sessions. Mindbloom suits adults 18 and over who live in one of its 38 listed states or Washington, D.C., and pass clinical screening. They also need an adult physically present for each session and a plan to pay out of pocket. Mindbloom does not suit anyone who wants insurance billing or an FDA-approved product given in a certified clinic.
The FDA's 2023 alert says at-home use of compounded ketamine carries added risk because no health care provider is onsite to monitor for sedation and dissociation. Mindbloom reports more than 800,000 sessions facilitated, by its own count.
Every new-client Mindbloom program bundles medicine for each session with clinician consults, guide coaching, a session kit and group support. The 6-session program's $1,290 price covers 3 guide coaching sessions plus unlimited messaging and 2 clinician consults. It also covers a Bloombox, unlimited group integration circles, app access and what Mindbloom calls 10+ programs, according to the pricing page.
The 12-session program raises the support to 4 guide coaching sessions and 3 clinician consults. The 18-session program includes 5 guide coaching sessions and 4 clinician consults. Both larger programs keep the Bloombox, the integration circles and app access.
Mindbloom's new-client program overview breaks the 6-session program into 2 clinician consults, 1 guide-led first session, 5 self-led sessions with clinician oversight and 2 one-on-one integration sessions with a guide. Mindbloom says completing 6 sessions typically takes two to three months. Extra one-on-one integration sessions with a guide cost $59 each.
The Bloombox is a kit for at-home sessions that Mindbloom says contains a medication compartment, a journal and an eye mask. Mindbloom also gives every client a blood pressure monitor to use under a clinician's direction, because ketamine can raise blood pressure. Integration circles are guide-led group sessions offered daily, and clients can join as many as they like.
The Mindbloom app includes guided soundscapes, intention setting, journaling and scheduling tools, according to the program page, and it is where clients complete the dose review after the first session. A clinician may prescribe one of two routes: rapidly dissolving tablets or subcutaneous injections under the skin of the abdomen. Mindbloom says the whole program runs online, with telemedicine appointments and medication shipped to the client's home.
Mindbloom sells programs as packages, and the per-session price falls as the package grows: $215 for 6 sessions, $185 for 12 and $165 for 18 for new clients. Those figures are the total program price divided by the number of sessions, as the help-center pricing article explains. The per-session figure is not a payment amount.
The new-client totals are $1,290, $2,220 and $2,970, paid as 3 installments of $430, 6 installments of $370 or 9 installments of $330. The arithmetic matches: 3 times $430 is $1,290, 6 times $370 is $2,220, and 9 times $330 is $2,970. Mindbloom's pricing page headline reads "as low as $165/session for new clients" and "No hidden fees," both company wording.
An initial payment is due at sign-up, and the remaining installments are charged at 30-day intervals. The payment schedule is separate from the treatment schedule, so spacing sessions further apart does not reduce or delay an installment. The installment plan does not renew automatically.
Mindbloom says tablets and injectables cost the same. On October 12, 2026, the tablets page and the injectables page displayed "$209/session for 6 sessions," while the pricing page and help center showed $215 per session and $1,290 in total. Before you pay, compare the checkout total with the $1,290 listed on the pricing page.
Returning clients pay less, according to the help center: $954 for 6 sessions in 3 installments of $318, or $2,322 for 18 sessions in 9 installments of $258. Those totals work out to $159 and $129 per session. The returning-client 6-session program includes 1 guide coaching session and 1 clinician consult, and the 18-session program includes 3 of each.
The pricing page showed a second set of returning-client figures on the same date. If you are a returning client, compare the total shown in your account with the help-center pricing article before you buy. A Care Advocate can review coupons and discounts, which Mindbloom says may be time-sensitive and depend on eligibility.
To set these totals beside other at-home pricing models, read the at-home ketamine therapy cost guide.
| Program | Total | Monthly installments | Per-session equivalent | Guide coaching sessions | Clinician consults |
|---|---|---|---|---|---|
| New client, 6 sessions | $1,290 | 3 × $430 | $215 | 3 | 2 |
| New client, 12 sessions | $2,220 | 6 × $370 | $185 | 4 | 3 |
| New client, 18 sessions | $2,970 | 9 × $330 | $165 | 5 | 4 |
| Returning client, 6 sessions | $954 | 3 × $318 | $159 | 1 | 1 |
| Returning client, 18 sessions | $2,322 | 9 × $258 | $129 | 3 | 3 |
Sources: Mindbloom pricing page and Mindbloom help center. The per-session figure is the program total divided by its sessions, not a payment amount. Extra one-on-one guide integration sessions are $59 each. Confirm the total at checkout.
Mindbloom does not accept insurance, so every program is paid out of pocket. After the first virtual visit, Mindbloom can provide a superbill, an itemized invoice you can submit to your insurer for possible out-of-network reimbursement. The billing codes Mindbloom lists are 99204 for the 45-minute initial consult and 99214 for the 25-minute medication management visit after Virtual Visit #1.
Any reimbursement depends on your insurer's approval. Some Mindbloom services may count as qualified health savings account (HSA) or flexible spending account (FSA) expenses, and Mindbloom says to try the card at checkout. Mindbloom adds that the card's processor makes the final decision on eligible expenses.
For how insurers handle ketamine care in general, read ketamine therapy insurance coverage.
Mindbloom's refund policy, dated September 3, 2026, ties cancellation fees to prescription shipments. For the new-client 6-session program, the refund is full if you cancel more than 24 hours before the clinician consult or a clinician finds you ineligible at that consult. A $150 cancellation fee applies if you cancel less than 24 hours before the consult.
The same $150 fee applies after a clinician finds you eligible but before the first prescription and Bloombox are ordered. Once those are ordered, and until the second prescription is ordered, the fee is $645, which is 50% of the $1,290 program. After the second prescription is ordered, the 6-session program is not eligible for any refund, so the fee equals the full $1,290.
The 12-session and 18-session schedules start with the same steps and add later fee tiers. The full $2,220 becomes non-refundable after the third prescription is ordered in the 12-session program. The full $2,970 becomes non-refundable after the fourth prescription is ordered in the 18-session program.
Mindbloom sets each fee by the number of shipments received. Time elapsed and medication used do not change the fee. If you cancel or are found ineligible to continue, Mindbloom says you pay only for care and resources already delivered.
Clients can also be disqualified mid-program for violating clinical protocols or for a newly identified health concern. Approved refunds are typically processed within 3 to 7 business days and go only to the original payment method.
A Mindbloom program starts with an online assessment and typically reaches a first treatment in less than 2 weeks, according to the getting-started article. If the assessment shows you are eligible, you buy a program and book a 45-minute virtual consultation with a licensed clinician authorized in your state. The clinician reviews your medical history, checks for contraindications and confirms whether ketamine is suitable.
If approved, you receive a personalized treatment plan, and if the clinician decides ketamine is not suitable, Mindbloom gives a full refund. A consultation is generally available within a week. Medication delivery follows within 3 to 6 business days after approval, with the medication and the Bloombox arriving in 2 separate shipments.
The clinician decides the route, injectables or tablets, at the initial consult. Mindbloom says about 75% of clients are approved for injectables, that approval depends on each person's health profile and that its injections are never intramuscular. Mindbloom also describes injection as having higher bioavailability and more predictable absorption than tablets.
You can share a preference, and the route can change at a later consult, according to Mindbloom's route article. A route change means repeating the titration protocol.
The first session is guide-led over a video call, with about 30 minutes of preparation before it and a reconnection with the guide afterward. After that session, you complete a dose review in the Mindbloom app, and the clinician reviews it within 72 hours. Session 2 is self-led, 3 to 7 days after session 1.
A follow-up clinician consult after session 2 reviews progress and plans sessions 3 to 6. Those later sessions are self-led and generally 7 to 14 days apart. One-on-one integration sessions of 45 minutes with a guide follow sessions 3 and 5.
For a general picture of a ketamine-assisted session outside any one company's program, read what to expect from ketamine-assisted therapy.
Mindbloom serves adults 18 and over in 38 states plus Washington, D.C., and offers both tablets and injectables in every listed state, according to its state list as of October 12, 2026. The states are Arizona, California, Colorado, Delaware, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, Nebraska, Nevada, New Jersey, New Mexico, New York, North Carolina, Ohio, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin and Wyoming. Mindbloom treatment is not available outside the United States.
Eligibility is decided case by case at the initial consultation, based on medical diagnoses, current medications and substance use history. A clinician may give conditional approval, with steps to meet eligibility. If the clinician finds you ineligible at the initial consult, the decision is final and the refund is full.
Mindbloom's safety page tells people not to proceed if they are allergic to ketamine or have symptoms of psychosis or mania, uncontrolled high blood pressure, congestive heart failure or another serious heart problem. The same list covers a severe breathing problem, a history of elevated intraocular or intracranial pressure, a history of hyperthyroidism and another serious medical illness. It also covers anyone who is pregnant, nursing or trying to become pregnant.
Every dosing session requires a Peer Treatment Monitor, a trusted adult 18 or older who is physically present at home or in the next room. Virtual presence is not permitted, and the monitor needs a working phone that can call and text. Mindbloom's guidance also says not to drive or operate heavy machinery after treatment until after a full night of sleep.
Compounded ketamine prescribed through Mindbloom is not FDA-approved for any mental health condition, and Mindbloom's own safety disclosure says so. That disclosure states that drugs compounded under Section 503A do not require FDA approval. It adds that FDA-approved ketamine products are approved as intravenous or intramuscular injections for general anesthesia, and none is approved in tablet or subcutaneous injectable form.
Ketamine is a Schedule III controlled substance under federal law, according to the U.S. Drug Enforcement Administration (DEA) drug scheduling page. For how that status applies to prescribing, read is ketamine legal in the U.S.
The FDA's compounding risk alert dated October 10, 2023, is listed on its Compounding Risk Alerts page. The alert text says ketamine is not FDA-approved for any psychiatric disorder, and that the FDA has not evaluated the safety, effectiveness or quality of compounded drugs before marketing. It also says at-home use of compounded ketamine presents additional risks because no health care provider is onsite to monitor for sedation and dissociation.
The alert says the FDA is not aware of evidence that compounded ketamine is safer, more effective or faster-acting than FDA-approved medications for certain psychiatric disorders. It also says the FDA has not established safe or effective dosing of ketamine for any psychiatric indication. In April 2023, the FDA received a report of a patient who had respiratory depression after taking compounded oral ketamine outside a health care setting for post-traumatic stress disorder (PTSD).
Mindbloom's own side-effect list includes sedation, dissociation, psychiatric events or worsening of psychiatric disorders, dependence, abuse and misuse, anxiety, and increased blood pressure or heart rate. The list continues with respiratory depression, lower urinary tract and bladder symptoms, nausea or vomiting, blurred vision and confusion. Mindbloom says ketamine has been found to cause moderate psychological dependency in some users.
The ketamine side effects guide covers these risks in more detail.
The same FDA alert names Spravato (esketamine) nasal spray as FDA-approved for treatment-resistant depression in adults, used with an oral antidepressant. The alert says Spravato is also approved, with an oral antidepressant, for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. Spravato's Risk Evaluation and Mitigation Strategy (REMS) requires it to be given in certified, medically supervised health care settings that monitor patients for at least two hours afterward. Compounded ketamine is not part of a REMS, and the Spravato vs ketamine comparison sets the two side by side.
Mindbloom's footer tells anyone in a life-threatening situation to call, text or chat 988.
Mindbloom's 2022 outcome study is an open-label study of its own clients with Mindbloom-affiliated co-authors, and it did not compare ketamine with another treatment. Hull and colleagues published it in the Journal of Affective Disorders in October 2022 (PubMed 35809678), and Mindbloom calls it "a peer-reviewed study of Mindbloom's client treatment outcomes." Open-label means participants and clinicians knew which treatment was being given.
The authors report that of 1,247 people who completed treatment with sufficient data, 62.8% reported a 50% or greater improvement on the Patient Health Questionnaire-9 (PHQ-9) depression scale. They report 62.9% on the Generalized Anxiety Disorder-7 (GAD-7) anxiety scale. The authors also report remission rates of 32.6% on the PHQ-9 and 31.3% on the GAD-7, with 0.9% and 0.6% deteriorating. Treatment lasted four weeks, and the authors wrote that future research should assess how long the effects last.
Four co-authors, Adam Gazzaley, Alok Madan, Leonardo Vando and Kristin Arden, are profiled on Mindbloom's safety page as members of its medical team or advisory board. Mindbloom's own disclosure says the FDA has not evaluated head-to-head trials comparing ketamine with FDA-approved medications for depression, anxiety or other psychiatric disorders. It also says outcomes some clients report may not be typical.
Mindbloom's research page lists more work on its client data. That includes a September 2024 Journal of Affective Disorders paper and a 2026 Journal of Medical Internet Research paper on subcutaneous ketamine that Mindbloom describes as covering 3,041 adults across 38 states. The page also lists several 2026 papers posted on a preprint server.
Mindbloom's program page compares its study results with separate studies of talk therapy, SSRI (selective serotonin reuptake inhibitor) antidepressants and intravenous (IV) ketamine. These cross-study comparisons are not head-to-head trials.
On the pricing page, several client testimonial videos carry a "Paid Partner" label, and Mindbloom states that results may vary and may not be representative of all clients. The "4.7/5 rating" on the same page is a figure Mindbloom displays itself.
Each item below comes from Mindbloom's published pages or the FDA's 2023 alert, as of October 12, 2026.
Mindbloom fits adults 18 and over in one of the 38 listed states or Washington, D.C., who are comfortable with at-home sessions. Each session also needs an adult who can be physically present. Mindbloom also fits people who plan to pay out of pocket and whom a clinician screens as eligible. Whether $1,290 to $2,970 is worth it is a decision to make with that clinician, against your own budget.
Mindbloom does not fit anyone outside the listed states or the United States, anyone under 18, or anyone with a contraindication on Mindbloom's list. It also does not fit someone without an available adult monitor, since virtual presence is not permitted.
If you want an FDA-approved product given in a certified, medically supervised setting, read the Spravato vs ketamine comparison. If insurance billing matters most, read what Spravato costs with insurance.
If you want a clinician onsite during each session, in-clinic ketamine is the category to compare, and the ketamine therapy cost guide covers it. If you want another online at-home service, compare options in the online ketamine therapy providers roundup.
This assessment would change if Mindbloom began accepting insurance, if the FDA approved ketamine for a psychiatric use in tablet or subcutaneous form, or if Mindbloom changed its state list or refund schedule.
Before you buy a program, read Mindbloom's refund schedule in full and bring the at-home ketamine safety checklist to your first clinician consult.
Mindbloom is a real, operating U.S. telehealth company that publishes its prices, refund policy and state list. Licensed clinicians at affiliated, independently owned practices screen clients and may prescribe compounded ketamine for at-home sessions. Being an operating business is separate from FDA approval, and compounded ketamine is not FDA-approved for any psychiatric use.
New-client programs are paid in monthly installments of $430 for 6 sessions, $370 for 12 sessions or $330 for 18 sessions, as of October 12, 2026. Those installments add up to $1,290, $2,220 and $2,970. Installments are charged every 30 days regardless of session pace, and the plan does not renew automatically.
No. Mindbloom does not accept insurance, but it can provide a superbill after the first virtual visit that you can submit for possible out-of-network reimbursement, subject to your insurer's approval. Some services may qualify as health savings account (HSA) or flexible spending account (FSA) expenses, and the card's processor makes that decision.
As of October 12, 2026, Mindbloom's help center lists 38 states plus Washington, D.C., with both tablets and injectables offered in each. The list includes California, Florida, New York, Texas and Washington, among others. Mindbloom treatment is not available outside the United States.
No. The compounded ketamine that Mindbloom's affiliated clinicians may prescribe is not FDA-approved for depression, anxiety or any psychiatric disorder. The FDA's October 2023 alert says at-home use adds risk because no health care provider is onsite. Spravato (esketamine) nasal spray is the FDA-approved product named in that alert, given in certified settings under a Risk Evaluation and Mitigation Strategy (REMS).
Yes, but the refund shrinks as prescriptions ship. For the 6-session program, cancelling more than 24 hours before the clinician consult, or being found ineligible there, brings a full refund. Later steps carry fees of $150 and then $645. After the second prescription is ordered, the full $1,290 is non-refundable, and refunds go only to the original payment method.
Mindbloom's pricing page shows client testimonial videos, several labeled "Paid Partner", and a "4.7/5 rating" that Mindbloom displays itself. Mindbloom says results may vary and may not be representative of all clients.
Get ketamine research & policy updates
New trials, FDA decisions, and legal changes for ketamine — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.